Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Shares Issued (2016 - 2025)

Editas Medicine (EDIT) has disclosed Shares Issued for 11 consecutive years, with $17.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued rose 5225.47% to $17.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.4 million, a 78.32% decrease, with the full-year FY2023 number at $117.1 million, up 38286.56% from a year prior.
  • Shares Issued was $17.1 million for Q3 2025 at Editas Medicine, up from $7.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $249.5 million in Q1 2021 to a low of -$248.9 million in Q3 2021.
  • A 5-year average of $26.2 million and a median of $322000.0 in 2024 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 1672300.0% in 2023; the steepest drop was 146461.25% in 2023.
  • Editas Medicine's Shares Issued stood at $248.9 million in 2021, then tumbled by 100.0% to $7000.0 in 2022, then soared by 1672300.0% to $117.1 million in 2023, then crashed by 100.28% to -$322000.0 in 2024, then skyrocketed by 5425.47% to $17.1 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Shares Issued are $17.1 million (Q3 2025), $7.2 million (Q2 2025), and $1.4 million (Q1 2025).